Physician profile
Samuel Walters
NPI 1336119817
$1,936.60
in general payments reported to CMS, 2019-2025
19 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.74 · 2021: $239 · 2022: $153 · 2023: $178 · 2024: $749 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.85 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $337.99 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $177.66 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $173.23 | 2019-2024 | Rybelsus, Ozempic |
| Dexcom, INC. | $140.57 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $128.13 | 2022 | |
| Inspire Medical Systems, INC. | $107.50 | 2024 | Inspire |
| Pfizer INC. | $73.46 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.84 | 2024 | Jardiance |
| Medtronic, INC. | $39.44 | 2022-2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $31.17 | 2024-2025 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $22.48 | 2025 | Veozah |
| Vertex Pharmaceuticals Incorporated | $20.36 | 2025 | |
| Amgen INC. | $17.78 | 2024 | Otezla, Repatha |
| Sanofi Pasteur INC. | $16.31 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.23 | 2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2024 | Zoryve |
| Corcept Therapeutics | $12.50 | 2021 | |
| Amarin Pharma, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.